Xinan Sheng

20PUBLICATIONS
75CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 02, 2026
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

|Dec 24, 2025
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.

Yelin Mulati, Qi Shen, Yuke Chen

|Oct 22, 2025
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Xinan Sheng, Gongqian Zeng, Cuijian Zhang

|Oct 21, 2025
MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Jiayuan Chen, Jiazhi Mo, Jinchang Wei

|May 12, 2025
Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets.

Xingming Zhang, Junjie Zhao, Xiaoxue Yin

Pageof 4

Frequent Collaborators

6 joint publications

Li Zhou

5 joint publications

Jiyan Liu

5 joint publications

Bixia Tang

4 joint publications

Lu Si